Skip to main content
. 2015 Apr 14;6(15):13790–13802. doi: 10.18632/oncotarget.3831

Figure 3. ARPCA inhibits the proliferation and angiogenic potential of FGF8b-dependent tumor cells.

Figure 3

A. S115 cells were treated with ARPCA or ARPVA in the presence of 30 ng/ml FGF8b or 10 nM DHT. Viable cells were counted 48 h thereafter. B. Western blot analysis of S115 cells treated with 30 ng/ml FGF8b in the absence or presence of 100 μM ARPCA or ARPVA. C. Alginate beads containing 2.5 × 104 DHT-treated S115 cells were grafted onto the CAM at day 11 of incubation in the absence or presence of the indicated doses of ARPCA or ARPVA. At day 14, newly formed blood vessels were counted (8 embryos/group). Data are the mean ± SEM. #P < 0.001.